These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4371994)

  • 21. [Plasmatic renin activity in essential arterial hypertension. Hyporeninemic hypertension].
    Gutiérrez Millet V; Casado Pérez S; Ruilope Urioste LM; Hernando Avendaño L
    Rev Clin Esp; 1975 Apr; 137(2):105-14. PubMed ID: 1144838
    [No Abstract]   [Full Text] [Related]  

  • 22. Relation between the hypotensive and renin-suppressing activities of alpha methyldopa in hypertensive patients.
    Leonetti G; Terzoli L; Morganti A; Manfrin M; Bianchini C; Sala C; Zanchetti A
    Am J Cardiol; 1977 Nov; 40(5):762-7. PubMed ID: 920613
    [No Abstract]   [Full Text] [Related]  

  • 23. Renin-aldosterone profiling in hypertension.
    Mitchell JR; Taylor AA; Pool JL; Lake CR; Rollins DE; Bartter FC
    Ann Intern Med; 1977 Nov; 87(5):596-312. PubMed ID: 335942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A kindred with familial glucocorticoid suppressible aldosteronism.
    Giebink GS; Gotlin RW; Biglieri EG; Katz FH
    J Clin Endocrinol Metab; 1973 Apr; 36(4):715-23. PubMed ID: 4346813
    [No Abstract]   [Full Text] [Related]  

  • 25. Infantile polycystic disease of the kidneys.
    Isdale JM; Thomson PD; Katz S
    S Afr Med J; 1973 Oct; 47(40):1892-6. PubMed ID: 4768666
    [No Abstract]   [Full Text] [Related]  

  • 26. Renin concentrations and effects of propranolol and spironolactone in patients with hypertension.
    Karlberg BE; Kågedal B; Tegler L; Tolagen K
    Br Med J; 1976 Jan; 1(6004):251-4. PubMed ID: 764929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of spironolactone (Aldactone) and methyldopa in low and normal renin hypertension.
    Solheim SB; Sundsfjord JA; Giezendanner L
    Acta Med Scand; 1975 Jun; 197(6):451-6. PubMed ID: 1098396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Spironolactone-induced changes of the renin-angiotensin-aldosterone system and blood pressure lowering in essential hypertension].
    Furrer J; Vetter W; Nussberger J; Beckerhoff R; Siegenthaler W
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():235-6. PubMed ID: 349929
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of essential hypertension with a combination of propranolol, spironolactone-thiabutazide and dihydralazine (author's transl)].
    Ebel H; Lübke H; Klaus D; Zehner J; Witzgall H
    Dtsch Med Wochenschr; 1978 Oct; 103(42):1650-5. PubMed ID: 699788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Equilibration of the treatment of severe arterial hypertension. Significance of d-1 propranolol].
    Ménard J; Corvol P; Alexandre JM; Meignan M; N'Guyen-Phanh-Tam
    Nouv Presse Med; 1975 Jan; 4(1):17-20. PubMed ID: 806894
    [No Abstract]   [Full Text] [Related]  

  • 31. Renin unresponsiveness and the effects of oxprenolol, methyldopa and spironolactone in pateints with essential hypertension.
    Thomas GW; Ledingham JG; Beilin LJ; Yeates KM
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):44-8. PubMed ID: 798576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged alteration of renin responsiveness after spironolactone therapy. A cause of false-negative testing for low-renin hypertension.
    Lowder SC; Liddle GW
    N Engl J Med; 1974 Dec; 291(23):1243-4. PubMed ID: 4422945
    [No Abstract]   [Full Text] [Related]  

  • 33. Therapy and prognosis of hypertension in chronic nephritis.
    Kajiwara N
    Jpn Circ J; 1975 Jul; 39(7):779-86. PubMed ID: 1159936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of systemic hypertension in children.
    Reisman L; Selden RV
    Pediatr Ann; 1982 Jul; 11(7):604-5, 607-10, 612-3. PubMed ID: 7050855
    [No Abstract]   [Full Text] [Related]  

  • 35. The renin-angiotensin-aldosterone system in normotensive and hypertensive patients with acromegaly.
    Strauch G; Vallotton MB; Touitou Y; Bricaire H
    N Engl J Med; 1972 Oct; 287(16):795-9. PubMed ID: 4341550
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacological basis of the symptomatic treatment of arterial hypertension. I. Hemodynamic effects, mechanisms of action and side effects of antihypertensive agents].
    Fournier A; Lagrue G; Schmitt H
    Nouv Presse Med; 1973 Oct; 2(38):2539-46. PubMed ID: 4148700
    [No Abstract]   [Full Text] [Related]  

  • 37. Minoxidil in refractory hypertension.
    Makker SP
    J Pediatr; 1975 Apr; 86(4):621-3. PubMed ID: 1092824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac hypertrophy in spontaneously hypertensive rats.
    Sen S; Tarazi RC; Khairallah PA; Bumpus FM
    Circ Res; 1974 Nov; 35(5):775-81. PubMed ID: 4371062
    [No Abstract]   [Full Text] [Related]  

  • 39. Essential hypertension in adolescents.
    Loggie J
    Postgrad Med; 1974 Nov; 56(6):133-40. PubMed ID: 4427856
    [No Abstract]   [Full Text] [Related]  

  • 40. [Essential hypertension: biochemical analysis--selective treatment].
    Bühler R; Laragh JH
    Schweiz Rundsch Med Prax; 1973 Apr; 62(16):489-91. PubMed ID: 4349069
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.